These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8436216)

  • 41. Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma.
    Guinn BA; Bosslet K; Lee C; Richardson D; Orchard K
    Eur J Haematol; 2011 Dec; 87(6):554-5. PubMed ID: 21883478
    [No Abstract]   [Full Text] [Related]  

  • 42. [BAFF level in bone marrow and expression of BAFF receptor on B cells in multiple myeloma patients].
    Zhou ZH; Zhang L; Pan QY; Huang BH; Zheng D; Liu JR; Li J; Luo SK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1131-4. PubMed ID: 23114133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma cell myeloma with histiocyte-like morphology.
    Zhu J; Pan B; Yao J; Guo W
    Int J Hematol; 2017 Sep; 106(3):307-309. PubMed ID: 28555415
    [No Abstract]   [Full Text] [Related]  

  • 44. Uptake of 57 Co vitamin B 12 by human haemopoietic cells in vitro.
    Wickrammasinghe SN; Carmel R
    Br J Haematol; 1972 Sep; 23(3):307-12. PubMed ID: 5080349
    [No Abstract]   [Full Text] [Related]  

  • 45. Growth factors and antiapoptotic signaling pathways in multiple myeloma.
    van de Donk NW; Lokhorst HM; Bloem AC
    Leukemia; 2005 Dec; 19(12):2177-85. PubMed ID: 16239913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bone marrow studies in myelomatosis.
    Hansen OP
    Scand J Haematol; 1978 Sep; 21(3):265-72. PubMed ID: 715378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of cobalamin inactivation on folate metabolism of leukemic cells.
    Ermens AA; Kroes AC; Schoester M; van Lom K; Lindemans J; Abels J
    Leuk Res; 1988; 12(11-12):905-10. PubMed ID: 3216671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atypical cobalamin deficiency. Subtle biochemical evidence of deficiency is commonly demonstrable in patients without megaloblastic anemia and is often associated with protein-bound cobalamin malabsorption.
    Carmel R; Sinow RM; Karnaze DS
    J Lab Clin Med; 1987 Apr; 109(4):454-63. PubMed ID: 3819580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different patterns of technetium-99m sestamibi uptake in multiple myeloma.
    Pace L; Catalano L; Pinto A; De Renzo A; Di Gennaro F; Califano C; Del Vecchio S; Rotoli B; Salvatore M
    Eur J Nucl Med; 1998 Jul; 25(7):714-20. PubMed ID: 9662593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis.
    Ribatti D; Nico B; Vacca A
    Int Rev Cell Mol Biol; 2015; 314():259-82. PubMed ID: 25619720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy.
    Nilsson-Ehle H
    Drugs Aging; 1998 Apr; 12(4):277-92. PubMed ID: 9571392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemical expression of cell cycle proteins in multiple myeloma.
    Pessach I; Papoudou-Bai A; Goussia A; Kamina S; Kyrtsonis MC; Bourantas KL; Kanavaros P
    Leuk Lymphoma; 2015; 56(9):2720-3. PubMed ID: 25573203
    [No Abstract]   [Full Text] [Related]  

  • 55. In vitro endocytosis of benign and malignant human bone marrow plasma cells.
    Ohtake K; Yano T; Kameda K; Ogawa T
    Am J Hematol; 1990 Oct; 35(2):100-3. PubMed ID: 2205094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mouse models and the RANKL/OPG axis in myeloma bone disease.
    Dingli D; Russell SJ
    Leukemia; 2007 Oct; 21(10):2090-3. PubMed ID: 17878922
    [No Abstract]   [Full Text] [Related]  

  • 57. Platelet-activating factor concentrations in bone marrow of patients with lymphoid and nonlymphoid hematologic malignancies.
    Denizot Y; Trimoreau F; Dupuis F; Verger C; Praloran V
    Leukemia; 1995 Nov; 9(11):1982-3. PubMed ID: 7475295
    [No Abstract]   [Full Text] [Related]  

  • 58. Morphometry and mathematical modelling of the capillary-like patterns formed in vitro by bone marrow macrophages of patients with multiple myeloma.
    Guidolin D; Nico B; Belloni AS; Nussdorfer GG; Vacca A; Ribatti D
    Leukemia; 2007 Oct; 21(10):2201-3. PubMed ID: 17525719
    [No Abstract]   [Full Text] [Related]  

  • 59. [Morphological diagnosis of plasmocytic myeloma in trephine biopsy (histological and immunohistochemical criteria)].
    Baĭkov VV
    Arkh Patol; 2007; 69(2):50-2. PubMed ID: 17642196
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DNA values in myeloma.
    Mundy GR
    Cancer; 1973 Jul; 32(1):61-8. PubMed ID: 4716785
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.